Vaccines (May 2022)
Safety of Vaccines against SARS-CoV-2 among Polish Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies
- Agata Czarnowska,
- Joanna Tarasiuk,
- Olga Zajkowska,
- Marcin Wnuk,
- Monika Marona,
- Klaudia Nowak,
- Agnieszka Słowik,
- Anna Jamroz-Wiśniewska,
- Konrad Rejdak,
- Beata Lech,
- Małgorzata Popiel,
- Iwona Rościszewska-Żukowska,
- Adam Perenc,
- Halina Bartosik-Psujek,
- Mariola Świderek-Matysiak,
- Małgorzata Siger,
- Agnieszka Ciach,
- Agata Walczak,
- Anna Jurewicz,
- Mariusz Stasiołek,
- Karolina Kania,
- Klara Dyczkowska,
- Alicja Kalinowska-Łyszczarz,
- Weronika Galus,
- Anna Walawska-Hrycek,
- Ewa Krzystanek,
- Justyna Chojdak-Łukasiewicz,
- Jakub Ubysz,
- Anna Pokryszko-Dragan,
- Katarzyna Kapica-Topczewska,
- Monika Chorąży,
- Marcin Bazylewicz,
- Anna Mirończuk,
- Joanna Kulikowska,
- Jan Kochanowicz,
- Marta Białek,
- Małgorzata Stolarz,
- Katarzyna Kubicka-Bączyk,
- Natalia Niedziela,
- Natalia Morawiec,
- Monika Adamczyk-Sowa,
- Aleksandra Podlecka-Piętowska,
- Monika Nojszewska,
- Beata Zakrzewska-Pniewska,
- Elżbieta Jasińska,
- Jacek Zaborski,
- Marta Milewska-Jędrzejczak,
- Jacek Zwiernik,
- Beata Zwiernik,
- Andrzej Potemkowski,
- Waldemar Brola,
- Alina Kułakowska
Affiliations
- Agata Czarnowska
- Department of Neurology, Medical University of Białystok, 15-276 Bialystok, Poland
- Joanna Tarasiuk
- Department of Neurology, Medical University of Białystok, 15-276 Bialystok, Poland
- Olga Zajkowska
- Faculty of Economic Sciences, University of Warsaw, 00-241 Warszawa, Poland
- Marcin Wnuk
- Department of Neurology, Jagiellonian University Medical College, 30-688 Krakow, Poland
- Monika Marona
- Department of Neurology, Jagiellonian University Medical College, 30-688 Krakow, Poland
- Klaudia Nowak
- Department of Neurology, Jagiellonian University Medical College, 30-688 Krakow, Poland
- Agnieszka Słowik
- Department of Neurology, Jagiellonian University Medical College, 30-688 Krakow, Poland
- Anna Jamroz-Wiśniewska
- Department of Neurology, Medical University of Lublin, 20-059 Lublin, Poland
- Konrad Rejdak
- Department of Neurology, Medical University of Lublin, 20-059 Lublin, Poland
- Beata Lech
- Neurology Clinic with Brain Stroke Sub-Unit, Clinical Hospital No. 2 in Rzeszow, 35-301 Rzeszow, Poland
- Małgorzata Popiel
- Neurology Clinic with Brain Stroke Sub-Unit, Clinical Hospital No. 2 in Rzeszow, 35-301 Rzeszow, Poland
- Iwona Rościszewska-Żukowska
- Department of Neurology, Institute of Medical Sciences, Medical College of Rzeszow University, 35-310 Rzeszow, Poland
- Adam Perenc
- Neurology Clinic with Brain Stroke Sub-Unit, Clinical Hospital No. 2 in Rzeszow, 35-301 Rzeszow, Poland
- Halina Bartosik-Psujek
- Department of Neurology, Institute of Medical Sciences, Medical College of Rzeszow University, 35-310 Rzeszow, Poland
- Mariola Świderek-Matysiak
- Department of Neurology, Medical University of Lodz, 90-419 Lodz, Poland
- Małgorzata Siger
- Department of Neurology, Medical University of Lodz, 90-419 Lodz, Poland
- Agnieszka Ciach
- Department of Neurology, Medical University of Lodz, 90-419 Lodz, Poland
- Agata Walczak
- Department of Neurology, Medical University of Lodz, 90-419 Lodz, Poland
- Anna Jurewicz
- Department of Neurology, Medical University of Lodz, 90-419 Lodz, Poland
- Mariusz Stasiołek
- Department of Neurology, Medical University of Lodz, 90-419 Lodz, Poland
- Karolina Kania
- Department of Neurology, Poznan University of Medical Sciences, 61-701 Poznan, Poland
- Klara Dyczkowska
- Faculty of Medicine, Poznan University of Medical Sciences, 61-701 Poznan, Poland
- Alicja Kalinowska-Łyszczarz
- Division of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, 61-701 Poznan, Poland
- Weronika Galus
- Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland
- Anna Walawska-Hrycek
- Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland
- Ewa Krzystanek
- Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland
- Justyna Chojdak-Łukasiewicz
- Department of Neurology, Wroclaw Medical University, 50-367 Wroclaw, Poland
- Jakub Ubysz
- Department of Neurology, Wroclaw Medical University, 50-367 Wroclaw, Poland
- Anna Pokryszko-Dragan
- Department of Neurology, Wroclaw Medical University, 50-367 Wroclaw, Poland
- Katarzyna Kapica-Topczewska
- Department of Neurology, Medical University of Białystok, 15-276 Bialystok, Poland
- Monika Chorąży
- Department of Neurology, Medical University of Białystok, 15-276 Bialystok, Poland
- Marcin Bazylewicz
- Department of Neurology, Medical University of Białystok, 15-276 Bialystok, Poland
- Anna Mirończuk
- Department of Neurology, Medical University of Białystok, 15-276 Bialystok, Poland
- Joanna Kulikowska
- Department of Neurology, Medical University of Białystok, 15-276 Bialystok, Poland
- Jan Kochanowicz
- Department of Neurology, Medical University of Białystok, 15-276 Bialystok, Poland
- Marta Białek
- Department of Neurology, Regional Specialised Hospital No. 4 in Bytom, 41-902 Bytom, Poland
- Małgorzata Stolarz
- Department of Neurology, Regional Specialised Hospital No. 4 in Bytom, 41-902 Bytom, Poland
- Katarzyna Kubicka-Bączyk
- Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland
- Natalia Niedziela
- Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland
- Natalia Morawiec
- Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland
- Monika Adamczyk-Sowa
- Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland
- Aleksandra Podlecka-Piętowska
- Department of Neurology, Medical University of Warsaw, 02-091 Warszawa, Poland
- Monika Nojszewska
- Department of Neurology, Medical University of Warsaw, 02-091 Warszawa, Poland
- Beata Zakrzewska-Pniewska
- Department of Neurology, Medical University of Warsaw, 02-091 Warszawa, Poland
- Elżbieta Jasińska
- Collegium Medicum, Jan Kochanowski University, 25-369 Kielce, Poland
- Jacek Zaborski
- Department of Neurology and Neurorehabilitation, Miedzyleski Szpital Specjalistyczny, 04-749 Warszawa, Poland
- Marta Milewska-Jędrzejczak
- Department of Neurology and Ischemic Strokes, Medical University of Lodz, 90-419 Lodz, Poland
- Jacek Zwiernik
- Neurology Ward, Provincial Specialist Hospital, 10-561 Olsztyn, Poland
- Beata Zwiernik
- Department of Neurology, University of Warmia and Mazury, 10-719 Olsztyn, Poland
- Andrzej Potemkowski
- Department of Clinical Psychology and Psychoprophylaxis, University of Szczecin, 70-204 Szczecin, Poland
- Waldemar Brola
- Collegium Medicum, Jan Kochanowski University, 25-369 Kielce, Poland
- Alina Kułakowska
- Department of Neurology, Medical University of Białystok, 15-276 Bialystok, Poland
- DOI
- https://doi.org/10.3390/vaccines10050763
- Journal volume & issue
-
Vol. 10,
no. 5
p. 763
Abstract
(1) Background: The present study aims to report the side effects of vaccination against coronavirus disease 2019 (COVID-19) among patients with multiple sclerosis (MS) who were being treated with disease-modifying therapies (DMTs) in Poland. (2) Methods: The study included 2261 patients with MS who were being treated with DMTs, and who were vaccinated against COVID-19 in 16 Polish MS centers. The data collected were demographic information, specific MS characteristics, current DMTs, type of vaccine, side effects after vaccination, time of side-effect symptom onset and resolution, applied treatment, relapse occurrence, and incidence of COVID-19 after vaccination. The results were presented using maximum likelihood estimates of the odds ratio, t-test, Pearson’s chi-squared test, Fisher’s exact p, and logistic regression. The statistical analyses were performed using STATA 15 software. (3) Of the 2261 sampled patients, 1862 (82.4%) were vaccinated with nucleoside-modified messenger RNA (mRNA) vaccines. Mild symptoms after immunization, often after the first dose, were reported in 70.6% of individuals. Symptoms included arm pain (47.5% after the first dose and 38.7% after the second dose), fever/chills/flu-like symptoms (17.1% after the first dose and 20.5% after the second dose), and fatigue (10.3% after the first dose and 11.3% after the second dose). Only one individual presented with severe side effects (pro-thrombotic complications) after vaccination. None of the DMTs in the presented cohort were predisposed to the development of side effects. Nine patients (0.4%) had a SARS-CoV-2 infection confirmed despite vaccination. (4) Conclusions: Vaccination against SARS-CoV-2 is safe for people with MS who are being treated with DMTs. Most adverse events following vaccination are mild and the acute relapse incidence is low.
Keywords
